SAN Sanofi

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range



Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Paris, July 31, 2025

Q2 sales growth of 10.1% at CER1 and business EPS2 of €1.59

  • Pharma launches increased sales by 39.8%, reaching €0.9 billion, driven by ALTUVIIIO
  • Dupixent sales increased by 21.1% to €3.8 billion, supported by the COPD launch
  • Vaccines sales increased by 10.3% to €1.2 billion
  • Research and Development expenses were €1.9 billion, up 17.7%
  • Selling, general and administrative expenses were €2.3 billion, up 7.8%
  • Business EPS was €1.59, up 8.3% at CER and up 1.9% reported; IFRS EPS was €3.24

Pipeline progress

  • Three regulatory approvals: Dupixent BP (US), Sarclisa NDMM, TE (EU), and MenQuadfi meningitis (US)
  • Three phase 3 readouts, incl. itepekimab COPD (one met primary endpoint/one did not); positive SP0087 in rabies prevention
  • Seven regulatory designations, including orphan and fast track, in rare diseases, neurology, and oncology

Capital allocation

  • Sanofi and CD&R closed the Opella transaction, creating an independent global consumer healthcare leader
  • Acquisitions completed: Blueprint, in rare diseases/immunology, and Dren Bio’s DR-0201, early-stage pipeline in immunology
  • Acquisitions announced: Vigil, in Alzheimer’s disease, and Vicebio, in respiratory vaccines, adding to the early-stage pipeline3

Sustainability

  • Sanofi ranked the world’s tenth most sustainable company and number one in Pharmaceuticals & Biotechnology by TIME

Guidance

  • In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER (before share buyback), now including all expenses from newly acquired businesses4
  • Sanofi intends to complete its €5 billion share buyback program in 2025. 80.3% has been repurchased to date

Paul Hudson, Chief Executive Officer: “We delivered strong performance in Q2 with 10.1% sales growth. Our nine newly launched medicines and vaccines grew by 47.3%. Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses.

Our pipeline continues to make progress despite the mixed results with itepekimab in COPD. We are progressing the data analysis and once finished, we will discuss with regulatory authorities. We remain steadfast in our dedication to bringing new medicines and vaccines to patients. We eagerly anticipate several important phase 3 data readouts in the second half of the year, including amlitelimab in atopic dermatitis and tolebrutinib in primary progressive multiple sclerosis.

Earlier in July, we successfully closed the acquisition of Blueprint in rare diseases, and we are anticipating the closing of the Vigil acquisition in neurology during Q3. Sanofi will remain focused on strategically redeploying capital towards growth and differentiated science with attractive financial returns. We continue to advance our strategy as an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth.”

 

  Q2 2025 Change Change

at CER
H1 2025 Change Change

at CER
IFRS net sales reported               €9,994m +6.0% +10.1%              €19,889m +8.3% +9.9%
IFRS net income reported               €3,939m +253.9% —                  €5,812m +158.8% —  
IFRS EPS reported                 €3.24   +264.0% —                   €4.74   +163.3% —  
Free cash flow5                €1,429m +65.8% —                 €2,458m +474.3% —  
Business operating income                €2,461m -2.4% +3.3           %               €5,363m +8.6% +10.8%
Business net income                €1,940m -0.6% +5.1           %                €4,152m +7.6% +9.8%
Business EPS                  €1.59   +1.9% +8.3%                 €3.39    +9.7% +12.0%

  

1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9).

2 To facilitate an understanding of operational performance, Sanofi comments on the business net income, a non-IFRS financial measure (definition in

Appendix 9). The income statement is in Appendix 3 and a reconciliation of net income as reported under IFRS to business net income is in Appendix 4.

3 Subject to closing conditions detailed overleaf.

4 Applying July 2025 average currency exchange rates, the currency impacts are estimated at around -4% on sales and at around -6% on business EPS.

5 Free cash flow is a non-IFRS financial measure (definition in Appendix 9).





 

Attachment



EN
31/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares - July 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry unde...

 PRESS RELEASE

Sanofi: Informations relatives au nombre de droits de vote et d'action...

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions...

 PRESS RELEASE

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the ...

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases Paris, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, ...

 PRESS RELEASE

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignati...

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Données de l’étude positive de phase 2 évaluant le rilzabrutinib pour le traitement de la maladie liée aux IgG4 présentée à l’EULAR de 2025Cette nouvelle désignation de médicament orphelin souligne l’engagement de Sanofi en faveur du développement de nouveaux médicaments contre les maladies rares à médiation immunitaire Paris, le 14 août 2025. ...

 PRESS RELEASE

Press Release: Sanofi completes the acquisition of Vigil Neuroscience,...

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc. Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of  (“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer’s disease. In addition, the acquisition of Vigil’s preclinical pipeline will further strengthen Sanofi’s research in various neurodegenerative diseases. In June 2024, Sanofi ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch